The High Grade Glioma Market was valued at USD 1.5 billion in 2024 and is projected to reach USD 3.2 billion by 2034, registering a CAGR of 8.1%. This growth trajectory is underpinned by several key factors, including the increasing incidence of high-grade gliomas, advancements in treatment modalities, and a growing focus on personalized medicine. High-grade gliomas, including glioblastomas,...